2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Payload
  5. Daunorubicins/Doxorubicins Isoform

Daunorubicins/Doxorubicins

Daunorubicin and doxorubicin are anthracycline anticancer drugs that act through DNA intercalation, topoisomerase II inhibition, DNA double-strand breaks, RNA synthesis inhibition, free-radical production, and apoptosis[1][2]. Mechanistically, anthracyclines also promote histone eviction from open chromatin, attenuate DNA repair through H2AX eviction, deregulate transcription, and affect cancer cells and heart tissue[3]. In disease and experimental models, these agents remain relevant for solid tumors, blood cancers, acute myeloid leukemia blasts, HL-60 leukemia cells, cardiomyocytes, and anthracycline-induced cardiotoxicity studies[2][3][4]. Compared with related topoisomerase II isoforms, TOP2α and TOP2β both serve as drug targets, but TOP2β is identified as a plausible cardiomyocyte target and a major intracellular mediator of doxorubicin-induced cardiotoxicity[5][6]. For experimental applications, liposomal doxorubicin lowers clinical heart failure versus conventional doxorubicin in adult solid tumors, while dexrazoxane and other catalytic TOP2 inhibitors protect cardiomyocytes without compromising anthracycline antiproliferative effects in HL-60 cells[4][7].

Daunorubicins/Doxorubicins Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-15142
    Doxorubicin hydrochloride
    		99.90%
    Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.
  • HY-13062
    Daunorubicin hydrochloride
    		99.67%
    Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.
  • HY-16700
    PNU-159682
    		98.50%
    PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
  • HY-13062A
    Daunorubicin
    		99.94%
    Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.
  • HY-128915
    Duocarmycin DM free base
    		99.69%
    Duocarmycin DM free base, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM free base is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.
  • HY-13061
    Daun02
    		98.72%
    Daun02 is a proagent of the topoisomerase inhibitor Daunorubicin.
  • HY-126666
    PNU-159682 carboxylic acid
    PNU-159682 carboxylic acid (Compound 53) is a potent ADCs cytotoxin and encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. PNU-159682 carboxylic acid has protein fold and diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response.
  • HY-15142A
    Doxorubicin
    Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy.
  • HY-130978
    Duocarmycin DM
    		99.15%
    Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.
  • HY-126665
    DMEA-PNU-159682
    DMEA-PNU-159682 (molecule D12) is a ADC cytotoxin molecule including metabolites of nemorubicin (MMDX) from liver microsomes and a potent ADCs cytotoxin PNU-159682.
  • HY-108876
    Daunorubicin citrate
    Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.